The controversial role of ABC transporters in clinical oncology

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) in cancer is frequently linked to ATP-binding cassette (ABC) transporter overexpression.
• Key MDR-associated ABC transporters include P-glycoprotein (Pgp/ABCB1), multidrug resistance-associated protein 1 (MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2).
• Decades of research have established a correlation between ABC transporter expression and poor patient outcomes in various cancer types.

Purpose of the Study:

• To review the historical development and clinical challenges of ABC transporter inhibitors in cancer therapy.
• To analyze the reasons for the lack of success in validating the 'Pgp hypothesis' and improving chemotherapy efficacy through transporter inhibition.
• To identify remaining obstacles and propose future directions for targeting ABC transporters in oncology.

Main Methods:

• Literature review and critical analysis of studies on ABC transporter inhibitors in cancer treatment.
• Examination of clinical trial data and outcomes related to transporter-targeted therapies.
• Discussion of the scientific and clinical hurdles encountered in developing effective ABC transporter inhibitors.

Main Results:

• Despite three generations of inhibitor development, the 'Pgp hypothesis'—that inhibiting transporter-mediated efflux enhances chemotherapy efficacy—remains unvalidated.
• Numerous clinical trials targeting ABC transporters have failed to demonstrate significant improvements in patient outcomes.
• Significant difficulties persist in developing clinically viable inhibitors that effectively target ABC transporters in cancer.

Conclusions:

• The clinical translation of targeting ABC transporters in cancer has been hindered by past failures and persistent challenges.
• Learning from previous setbacks is crucial for future efforts to develop ABC transporters as effective targets for cancer intervention.
• Further research is needed to overcome the complexities of ABC transporter-mediated drug resistance and to develop successful therapeutic strategies.